Fucoidan Improves the Metabolic Profiles of Patients With Non-alcoholic Fatty Liver Disease (NAFLD)

Taipei Medical University

Status: Completed

Conditions: Non-alcoholic Fatty Liver Disease

Treatments: Other: placebo pills; Other: 275mg Oligo Fucoidan + 275mg HS Fucoxanthin

Study type: Interventional

Funder types: Other

Identifiers

NCT02875392

N201605071

Details and patient eligibility

About

Studies reveal special function of fucoidan so far include anti-virus, anti-tumor, immunomodulatory, anti-inflammatory, blood fat, anti-oxidation and liver and kidney dysfunction and improve fibrosis. The subject of this study focus on assessing the impact on the metabolism of fatty liver and liver fibrosis after taking oral FucoHiQ capsules.

Full description

Fucoidan is a water-soluble dietary fiber which is extracted from brown seaweed. Slimy surface of brown seaweed has unique ingredients and different kind of brown seaweed has slightly different effectiveness. The strongest fucoidan among all seaweed for inhibiting cancer cells is in Okinawa Japanese waters. For chemically speaking, the major components for fucoidan consisted of mainly fucose which is a kind of polysaccharide with strong biological activity. However, patients need to take actual fucoidan in order to reach the best effectiveness for inhibiting cancer cell.

Studies reveal special function of fucoidan so far include anti-virus, anti-tumor, immunomodulatory, anti-inflammatory, blood fat, anti-oxidation and liver and kidney dysfunction and improve fibrosis. The subject of this study focus on assessing the impact on the metabolism of fatty liver and liver fibrosis after taking oral FucoHiQ capsules.

Enrollment: 57 patients

Sex: All

Ages: 20 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients who are aged between 20-75 with non alcoholic fatty liver disease (NAFLD).

Exclusion criteria

1. Patients were allergic to seafood.
2. Patients who take Vitamin E or Pioglitazone.

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

57 participants in 2 patient groups, including a placebo group

Fucoidan use

Experimental group

Description:

FucoHiQ(275mg Oligo Fucoidan + 275mg HS Fucoxanthin) 550mg/capsule 6 per day(before breakfast and supper)

Treatment:

Other: 275mg Oligo Fucoidan + 275mg HS Fucoxanthin

placebo pills

Placebo Comparator group

Description:

placebo capsule 6 per day (before breakfast and supper)

Treatment:

Other: placebo pills